Article Details

Scancell in-licenses Vaccitech's SNAPvax tech for cancer study - Labiotech.eu

Retrieved on: 2022-11-07 21:01:01

Tags for this article:

Click the tags to see associated articles and topics

Scancell in-licenses Vaccitech's SNAPvax tech for cancer study - Labiotech.eu. View article details on hiswai:

Excerpt

The company expects that the combination of Scancell's Modi-2 with a highly effective platform for inducing T cells – Vaccitech's SNAPvax technology – ...

Article found on: www.labiotech.eu

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up